Detalhe da pesquisa
1.
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Oncologist
; 23(8): 943-947, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29622697
2.
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Kidney Int Rep
; 7(3): 494-506, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257062
3.
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Clin Pharmacol Ther
; 109(2): 372-382, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32599652
4.
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Clin J Am Soc Nephrol
; 16(7): 1025-1036, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33985991
5.
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Clin Pharmacol Ther
; 108(1): 63-72, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31994716
6.
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Clin Cancer Res
; 21(12): 2666-70, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25802282